Blau Farmacêutica (BLAU3) Q4 2024 earnings summary

Executive summary

• Achieved record net income and net revenue of BRL 1.75 billion in 2024, up 28% year-over-year, driven by strong revenue growth, margin expansion, and working capital optimization.

• Recurring EBITDA rose 51% to BRL 391 million, with margin up 340 bps to 22.3% in 2024, supported by gross margin improvement and expense dilution.

• Strategic investments in biotechnology, R&D, and capacity expansion support long-term growth and global ambitions.

• Financial position strengthened with net debt reduced by 85% to BRL 24 million and leverage at 0.1x.

• Free cash flow to firm surged to BRL 276 million in 2024, reflecting operational and tax optimization.

Financial highlights

• Net revenue reached BRL 1.75 billion in 2024, up 28% year-over-year; 4Q24 net revenue was BRL 456 million, up 18%.

• Gross margin improved to 40.0% for 2024 (+900 bps); 4Q24 gross margin was 37.5% (+180 bps).

• Recurring EBITDA margin was 22.3% in 2024 (+340 bps); 4Q24 margin reached 25.6%.

• Recurring net income was BRL 220 million in 2024 (+23%); 4Q24 net income was BRL 57 million (+81%).

• Free cash flow to firm was BRL 276 million in 2024, 23x higher than 2023.

Outlook and guidance

• Focus on launching new products, expanding market share, and global expansion, with continued investments in R&D and capacity.

• Management expects continued growth in 2025, emphasizing execution consistency and biotechnology investments.